Scinai Immunotherapeutics Secures Israel Innovation Authority Grant
Ticker: SCNI · Form: 6-K · Filed: Oct 6, 2025 · CIK: 1611747
| Field | Detail |
|---|---|
| Company | Scinai Immunotherapeutics Ltd. (SCNI) |
| Form Type | 6-K |
| Filed Date | Oct 6, 2025 |
| Risk Level | low |
| Pages | 1 |
| Reading Time | 1 min |
| Sentiment | bullish |
Sentiment: bullish
Topics: grant, cdmo, expansion, funding
TL;DR
Scinai gets grant from Israel Innovation Authority to boost CDMO ops.
AI Summary
On October 6, 2025, Scinai Immunotherapeutics Ltd. announced it received a grant from the Israel Innovation Authority. This funding will be used to expand its fill-and-finish Contract Development and Manufacturing Organization (CDMO) capabilities.
Why It Matters
This grant will enhance Scinai's CDMO services, potentially attracting more clients and increasing revenue streams in the biopharmaceutical manufacturing sector.
Risk Assessment
Risk Level: low — The filing is a routine announcement of a grant award, with no immediate negative financial or operational implications.
Key Players & Entities
- Scinai Immunotherapeutics Ltd. (company) — Filer of the report
- Israel Innovation Authority (company) — Granting body
- October 6, 2025 (date) — Date of announcement
FAQ
What is the purpose of the grant awarded to Scinai Immunotherapeutics Ltd.?
The grant from the Israel Innovation Authority is intended to expand Scinai's fill-and-finish Contract Development and Manufacturing Organization (CDMO) capabilities.
Who awarded the grant to Scinai Immunotherapeutics Ltd.?
The grant was awarded by the Israel Innovation Authority.
On what date was the grant announcement made?
The announcement of the grant was made on October 6, 2025.
What type of capabilities will be expanded with the grant funding?
The grant will be used to expand fill-and-finish CDMO capabilities.
Is Scinai Immunotherapeutics Ltd. required to file annual reports under Form 20-F or Form 40-F?
Scinai Immunotherapeutics Ltd. indicates it files annual reports under Form 20-F.
Filing Stats: 269 words · 1 min read · ~1 pages · Grade level 11.2 · Accepted 2025-10-06 07:45:24
Filing Documents
- ea0260358-6k_scinai.htm (6-K) — 11KB
- ea026035801ex99-1_scinai.htm (EX-99.1) — 15KB
- 0001213900-25-096290.txt ( ) — 27KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. Scinai Immunotherapeutics Ltd. Date: October 6, 2025 By: /s/ Amir Reichman Amir Reichman Chief Executive Officer 2